Translating IL-6 biology into effective treatments

Choy, Ernest H. ORCID: https://orcid.org/0000-0003-4459-8609, De Benedetti, Fabrizio, Takeuchi, Tsutomu, Hashizume, Misato, John, Markus R. and Kishimoto, Tadamitsu 2020. Translating IL-6 biology into effective treatments. Nature Reviews Rheumatology 16 , pp. 335-345. 10.1038/s41584-020-0419-z

Preview

PDF - Accepted Post-Print Version Download (471kB) | Preview

Abstract

In 1973, IL-6 was identified as a soluble factor that is secreted by T cells and is important for antibody production by B cells. Since its discovery more than 40 years ago, the IL-6 pathway has emerged as a pivotal pathway involved in immune regulation in health and dysregulation in many diseases. Targeting of the IL-6 pathway has led to innovative therapeutic approaches for various rheumatic diseases, such as rheumatoid arthritis, juvenile idiopathic arthritis, adult-onset Still’s disease, giant cell arteritis and Takayasu arteritis, as well as other conditions such as Castleman disease and cytokine release syndrome. Targeting this pathway has also identified avenues for potential expansion into several other indications, such as uveitis, neuromyelitis optica and, most recently, COVID-19 pneumonia. To mark the tenth anniversary of anti-IL-6 receptor therapy worldwide, we discuss the history of research into IL-6 biology and the development of therapies that target IL-6 signalling, including the successes and challenges and with an emphasis on rheumatic diseases.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Nature Publishing Group
ISSN:	1759-4790
Date of First Compliant Deposit:	20 May 2020
Date of Acceptance:	31 March 2020
Last Modified:	07 Nov 2023 23:53
URI:	https://orca.cardiff.ac.uk/id/eprint/131835

Citation Data

Cited 282 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item